Ertapenem in Patients With Urosepsis
Ertapenem in Patients With Urosepsis
Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity
 agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America
 and Europe for several clinical use in complicated intraabdominal infections, complicated
 skin and skin-structure infections, acute pelvic infections, complicated urinary tract
 infections and community-acquired pneumonia. In common with other beta-lactams, ertapenem
 exhibits primarily time-dependent activity, and the percentage of the exposure time during
 which the free drug concentration remain above the MIC (%T>MIC) is the
 pharmacokinetic/pharmacodynamics (PK/PD) index that best correlates with efficacy.
 Pathophysiological changes in critically ill patients with severe infections resulting in
 altered PK patterns that may affect therapeutic plasma concentrations and achievement of PD
 have been found with several antimicrobial agents. The aim of the study was to determine the
 PK of ertapenem in patients with urosepsis.
Inclusion Criteria:

 -  >18 years of age

 -  Diagnosis of urosepsis

 Exclusion Criteria:

 -  They were pregnant

 -  Circulatory shock (defined as a systolic blood pressure of < 90 mmHg and pour tissue
 perfusion)

 -  Documented hypersensitivity to carbapenems

 -  Estimated creatinine clearance (CLcr) (determined by the Crockcroft-Goult method) of <
 30 mL/min